LIXTE Biotechnology Holdings announced the appointment of Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who previously facilitated LIXTE’s November 2025 acquisition of Liora’s assets, brings more than 20 years of healthcare operational and strategic advisory experience to the role. Management stated the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.
Braun will lead advancement of Liora’s LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Proton therapy represents a precise form of radiation treatment that targets tumors while minimizing damage to surrounding healthy tissue. The LiGHT System’s electronic control aims to improve the delivery and effectiveness of this technology for cancer patients. The appointment of Braun to lead the European subsidiary represents a strategic move to expand LIXTE’s presence in the cancer radiotherapy market. By pursuing a recurring revenue model, the company aims to create sustainable business operations around the LiGHT System technology. This approach could provide more consistent financial returns compared to one-time equipment sales while supporting ongoing technological development and patient access to advanced proton therapy treatments.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company advancing cancer treatments. The company has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology called activation lethality that is advancing a new treatment paradigm. The company’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
This executive appointment comes as LIXTE seeks to integrate its pharmaceutical and medical technology divisions to create a comprehensive cancer treatment approach. The combination of LB-100’s potential to enhance existing cancer therapies with the LiGHT System’s advanced proton delivery technology represents a dual-pronged strategy in oncology treatment development. The full terms of use and disclaimers applicable to all content provided by IBN are available at http://IBN.fm/Disclaimer. Certain statements in the announcement are forward-looking as defined in the Private Securities Litigation Reform Act of 1995 and involve risks, uncertainties, and other factors that may cause actual results to differ materially from expressed expectations.
